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For a review of the 2010 influenza season, please refer to the website 
of the National Institute for Communicable Diseases of the National 
Health Laboratory Service: www.nicd.ac.za 
Recommended vaccine formulation
The following strains have been recommended by the World Health 
Organization (WHO) for the 2011 Southern Hemisphere influenza 
season and are the same as the recommendations for the 2010 
season:
•    an A/California/7/2009 (H1N1)-like virus
•    an A/Perth/16/2009 (H3N2)-like virus
•    a B/Brisbane/60/2008-like virus.
Vaccines should contain 15 μg of each haemagglutinin antigen in 
each 0.5 ml dose.
Indications
1.   Persons (adults or children) who are at high risk for influenza 
and its complications because of underlying medical conditions 
and who are receiving regular medical care for conditions such as 
chronic pulmonary and cardiac diseases, chronic renal diseases, 
diabetes mellitus and similar metabolic disorders, individuals who 
are immunosuppressed (including HIV- infected persons with 
CD4 counts above 100 cells/µl), individuals who are morbidly 
obese (BMI ≥40).
2.    Pregnant women, irrespective of stage of pregnancy.
3.    Residents of old-age homes, chronic care and rehabilitation 
institutions.
4.    Children on long-term aspirin therapy.
5.    Medical and nursing staff responsible for the care of high-risk 
cases.
6.    Adults and children who are family contacts of high-risk cases.
7.    All persons over the age of 65 years. 
8.    Any persons wishing to protect themselves from the risk of 
contracting influenza, especially in industrial settings, where 
large-scale absenteeism could cause significant economic losses.
Dosage
•    Adults:  Whole or split-product or subunit vaccine – 1 dose IM.
•    Children (<12 years):  Split-product or subunit vaccine – 1 dose IM.
•    Children <9 years who have never been vaccinated should receive 
2 doses 1 month apart.
•    Children <3 years of age should receive half the adult dose on two 
occasions separated 1 month apart.
•    Influenza vaccine is not recommended for infants less than 6 
months of age.
Contraindications
1.    Persons with a history of severe (anaphylactic) hypersensitivity to 
eggs or other components of the vaccine.
2.    Persons with acute febrile illnesses should preferably be immunised 
after symptoms have resolved.
Timing
Vaccines should be given sufficiently early to provide protection for the 
winter.  A protective antibody response takes about 2 weeks to develop.
Antiviral chemotherapy
At present novel influenza A (H1N1) and H3N2 and B influenza 
viruses remains largely sensitive to oseltamivir (as well as zanamivir). 
The dosages for treatment are provided in Table I.
Antiviral chemoprophylaxis  
Chemoprophylaxis for contacts of persons with influenza is not 
recommended. Recent WHO recommendations advise presumptive 
treatment using the treatment regimen described above for high-risk 
(severely immunocompromised) individuals exposed to influenza 
instead of the previously recommended long-term lower-dose 
chemoprophylaxis regimen. These individuals need to be very 
carefully monitored during influenza outbreak season for early signs 
and should then be treated immediately on suspicion of infection.
For a more detailed description of antiviral management and 
prophylaxis of influenza, please refer to the Healthcare Workers 
Handbook on Influenza on the NICD website:  http://www.nicd.ac.za 
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Table I. Recommended dosage of antiviral agents for treatment 
Age group Weight Oseltamivir 
dosage*
Zanamivir dosage*
Adults 75 mg twice a day 
Two 5 mg 
inhalations (10 mg 
total) twice a day 
Children Premature 
neonates 
(<38 wks)
1.0 mg/kg dose 
twice a day
Two 5 mg 
inhalations (10 mg 
total) twice a day 
(only in children 
aged 5 years or 
older) 
Infants 0 - 
12 months
3.0 mg/kg dose 
twice a day
15 - 23 kg 45 mg twice a day
24 - 40 kg 60 mg twice a day
>40 kg 75 mg twice a day
*Recommended duration of treatment is 5 days. Zanamivir is only registered for children ≥5 
years of age.
